CanSino Biologics reports fever, fatigue reactions to coronavirus vaccine, shares sink by 13pcBusiness | 25 May 2020 4:05 pm
Chinese company CanSino Biologics, which carried out a trial of a genetically-engineered coronavirus vaccine candidate in 108 healthy young male and female adults in Wuhan between March 16 and 27, said it caused adverse reactions.
The vaccine warrants further investigation, CanSino Biologics said in a statement.
CanSino Biologics (6185) shares sank by 13.92 percent at HK$191.10 at the close
The vaccine candidate is developed by CanSino Biologics and Beijing Institute of Biotechnology, Academy of Military Medical Sciences.
The 108 Wuhan adults (51 percent male, 49 percent female, aged 36.3 years on average) received doses ranging from low to high. Wuhan in Hubei province, was once the coronavirus epicenter in mainland China.
In the first seven days after vaccination, 30 adults, or 83 percent in the low dose group, 30 (or 83 percent) in the middle dose group, and 27 (or 75 percent) in the high dose group reported adverse reactions.
The most common injection site adverse reaction was pain, which was reported in 58 (or 54 percent) of those vaccinated. The most commonly reported systematic adverse reactions were fever (50 [46 percent]), fatigue (47 [44 percent]), headache (42 [39 percent]), and muscle pain (18 [17 percent].
Most adverse reactions that were reported in all dose groups were mild or moderate in severity, the company said.
No serious adverse event was noted within 28 days post-vaccination, CanSino Bio said.